Scientists behind the ‘Baby KJ’ bespoke CRISPR treatment have launched Aurora Therapeutics with seed backing to develop personalized gene‑editing medicines for ultra‑rare mutations. Menlo Ventures led initial funding as the team — including founder Fyodor Urnov and advisors tied to Jennifer Doudna — aims to pursue groupings of mutations under emerging regulatory frameworks. Aurora’s inaugural focus is phenylketonuria (PKU), where numerous causative variants complicate one‑by‑one drug development. The company intends to use adaptive regulatory pathways that allow variant‑grouped approvals and to scale design and manufacturing tools for individualized editing constructs.